$AstraZeneca PLC(AZN)$ AstraZeneca ($AZN) is staging a comeback, jumping ~7% to test key £125 resistance.
The primary catalysts behind the push:
* £7.2M Insider Buy: CEO Pascal Soriot personally purchased 60,000 shares, sending a massive vote of confidence to the market.
* Clinical Momentum: Fresh lung cancer trial progress reaffirmed leadership in high-margin oncology.
* Analyst Upgrades: Deutsche Bank upgraded the stock, while Goldman Sachs hiked its target price on pipeline longevity.
* Fundamental Beat: Builds on a clean Q2 earnings beat ($2.63 core EPS vs. $2.50 consensus).
With executive skin in the game and pipeline execution firing, momentum has firmly flipped back to the bulls.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
